Moderna plans to file for EUA of COVID-19 shot for very young kids by April end

Moderna plans to submit an application to the US health regulator for Emergency Use Authorisation (EUA) of its COVID-19 vaccine among kids between the ages of six months to five years by end of the month, a company spokesperson said recently.

The Omicron variant was predominant during Moderna’s paediatric trial, and the drugmaker said two doses were around 38 per cent effective in preventing infections in two-to-five-year-olds and 44 per cent effective for children aged six months to under two years.

Last week, Pfizer and BioNTech said a third dose of the COVID-19 vaccine produced significant protection against the Omicron variant in healthy children from ages five to 11 years.

Earlier this year, the US Food and Drug Administration (FDA) authorised a third dose of the Pfizer/BioNTech vaccine for children aged 12 to 15 years and those aged five through 11 who are immunocompromised.

Edits by EP News Bureau